Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto.  She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 400 peer-reviewed papers, and has mentored many trainees that have gone on to leadership roles in oncology around the world, and received the American Society of Clinical Oncology Excellence in Teaching Award in 2019.

Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics including liquid biopsy. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She chairs the ASCO Thoracic Advisory Guidelines Group, the ESMO Metastatic Lung Cancer Faculty Track and ESMO Early stage Guidelines Committee. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees. She is also a member of the IASLC Board of Directors.